Business
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients
Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"text","content":"\nAgreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland\n\n LONDON--(BUSINESS WIRE)--\nVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has reached an agreement with the Swiss Federal Office of Public Health (FOPH) and the Swiss Federal Social Insurance Office (FSIO) for the reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for eligible patients in Switzerland living with cystic fibrosis (CF).\n\n\nUnder the terms of the agreement announced today, eligible patients ages two years and older with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can be treated with ORKAMBI®. Eligible patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and another responsive residual function mutation in the CFTR gene, can be treated with SYMDEKO®. The agreement also includes any future indication extensions for patients of different ages for SYMDEKO®.\n\n\nThis agreement also enables the possibility for rapid patient access to a potential future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) pending marketing authorization from Swissmedic, the Swiss Agency for Therapeutic Products. Vertex submitted an application to Swissmedic on March 24, 2020.\n\n\nCommenting about today’s news in Switzerland, Ludovic Fenaux, Senior Vice President, Vertex International, said, “This agreement is an important milestone for the cystic fibrosis community in Switzerland. Access to Orkambi and Symdeko is especially important at this time given the COVID-19 outbreak and that people with CF are vulnerable to infections. We are pleased that Vertex and the Swiss authorities have been able to work closely and flexibly to enable this agreement, so that almost 400 eligible Swiss patients will now have access to CFTR modulators to treat the underlying cause of their disease.”\n\n\nVertex’s CF medicines are reimbursed in more than 20 countries around the world including Australia, France, Germany, the Republic of Ireland, Italy, the Netherlands, Spain, Sweden, the UK and the U.S.\n\n\nAbout Cystic Fibrosis\n\n\nCystic ...